We firmly believe that, with the refinement of related basic and clinical experiments, KIF3C holds the potential to emerge as a novel therapeutic target for gastric cancer, offering promise for improved outcomes among gastric cancer patients. This evidence concerns the gene KIF3C and gastric cancer.